CASP1 and amyotrophic lateral sclerosis: Therefore, the specific inhibition of NLRP3 does not seem to be a good therapeutic approach for ALS, and it would be better to act at other levels of the pro-inflammatory cascade of inflammasomes, such as caspase 1, IL1β [31] or all inflammasome components at once [56].